会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 85. 发明申请
    • SYNCHRONIZATION OF THE CYTOPLASMATIC AND THE NUCLEAR MATURATION OF OOCYTES <i>IN VITRO</i>
    • 细胞色素的同步化和体外成分的核苷酸的同步
    • WO0176360A3
    • 2002-01-24
    • PCT/DK0100239
    • 2001-04-06
    • NOVO NORDISK ASSCHERING AGANDERSEN CLAUS YDINGBYSKOV ANNE GRETE
    • ANDERSEN CLAUS YDINGBYSKOV ANNE GRETE
    • A61K35/48A61P15/08C12N5/075C12N5/08A61K38/24
    • C12N5/0609
    • The present invention relates to a method for in vitro maturation of oocytes comprising the steps of: (a) culturing one or more GV oocytes in a culture medium, the culture medium comprising a nuclear maturation inhibiting substance and comprising one or more gonadotropins and/or one or more growth factors, the culturing taking place for a time period sufficient for cytoplasmatic maturation to occur; (b) washing the GV oocytes of step (a) to remove the nuclear maturation inhibiting substance; (c) culturing the washed oocytes of step (b) in a culture medium comprising one or more gonadotropins and/or one or more growth factors and/or MAS for a time period sufficient for nuclear maturation. The invention also relates to an oocyte culture medium comprising a nuclear maturation inhibiting substance and comprising one or more gonadotropins and/or one or more growth factors. The nuclear maturation inhibiting substance may be a MAS antagonist or an FF-MAS synthesis inhibitor, preferably a cytochrome P450 Panosterol 14 alpha -demethylase (P45014DM) inhibitor e.g. ketoconazole or 22-hydroxycholesterol. The one or more gonadotropins and/or one or more growth factors are preferably a combination of EGF and FSH and/or LH. The invention also relates to the use of a nuclear maturation inhibiting substance and one or more gonadotropins and/or one or more growth factors as described above for the preparation of a cell culture medium for in vitro maturation of oocytes.
    • 本发明涉及卵母细胞体外成熟的方法,其包括以下步骤:(a)在培养基中培养一种或多种GV卵母细胞,所述培养基包含核成熟抑制物质,并且包含 一种或多种促性腺激素和/或一种或多种生长因子,培养发生足以发生细胞质成熟的时间段; (b)洗涤步骤(a)的GV卵母细胞以去除核成熟抑制物质; (c)在包含一种或多种促性腺激素和/或一种或多种生长因子和/或MAS的培养基中培养步骤(b)的洗涤的卵母细胞足以进行核成熟的时间段。 本发明还涉及包含核成熟抑制物质并包含一种或多种促性腺激素和/或一种或多种生长因子的卵母细胞培养基。 核成熟抑制物质可以是MAS拮抗剂或FF-MAS合成抑制剂,优选细胞色素P450 Panosterol14α-二甲基化酶(P45014DM)抑制剂。 酮康唑或22-羟基胆固醇。 一种或多种促性腺激素和/或一种或多种生长因子优选是EGF和FSH和/或LH的组合。 本发明还涉及如上所述的核成熟抑制物质和一种或多种促性腺激素和/或一种或多种生长因子用于制备卵母细胞体外成熟的细胞培养基的用途 。
    • 86. 发明申请
    • SYNCHRONIZATION OF THE CYTOPLASMATIC AND THE NUCLEAR MATURATION OF OOCYTES <i>IN VITRO</i>
    • 细胞色素的同步化和体外成分的核苷酸的同步
    • WO01076360A2
    • 2001-10-18
    • PCT/DK2001/000239
    • 2001-04-06
    • A61K35/48A61P15/08C12N5/075A01K67/027
    • C12N5/0609
    • The present invention relates to a method for in vitro maturation of oocytes comprising the steps of: (a) culturing one or more GV oocytes in a culture medium, the culture medium comprising a nuclear maturation inhibiting substance and comprising one or more gonadotropins and/or one or more growth factors, the culturing taking place for a time period sufficient for cytoplasmatic maturation to occur; (b) washing the GV oocytes of step (a) to remove the nuclear maturation inhibiting substance; (c) culturing the washed oocytes of step (b) in a culture medium comprising one or more gonadotropins and/or one or more growth factors and/or MAS for a time period sufficient for nuclear maturation. The invention also relates to an oocyte culture medium comprising a nuclear maturation inhibiting substance and comprising one or more gonadotropins and/or one or more growth factors. The nuclear maturation inhibiting substance may be a MAS antagonist or an FF-MAS synthesis inhibitor, preferably a cytochrome P450 Panosterol 14 alpha -demethylase (P45014DM) inhibitor e.g. ketoconazole or 22-hydroxycholesterol. The one or more gonadotropins and/or one or more growth factors are preferably a combination of EGF and FSH and/or LH. The invention also relates to the use of a nuclear maturation inhibiting substance and one or more gonadotropins and/or one or more growth factors as described above for the preparation of a cell culture medium for in vitro maturation of oocytes.
    • 本发明涉及卵母细胞体外成熟的方法,其包括以下步骤:(a)在培养基中培养一种或多种GV卵母细胞,所述培养基包含核成熟抑制物质,并且包含 一种或多种促性腺激素和/或一种或多种生长因子,培养发生足以发生细胞质成熟的时间段; (b)洗涤步骤(a)的GV卵母细胞以去除核成熟抑制物质; (c)在包含一种或多种促性腺激素和/或一种或多种生长因子和/或MAS的培养基中培养步骤(b)的洗涤的卵母细胞足以进行核成熟的时间段。 本发明还涉及包含核成熟抑制物质并包含一种或多种促性腺激素和/或一种或多种生长因子的卵母细胞培养基。 核成熟抑制物质可以是MAS拮抗剂或FF-MAS合成抑制剂,优选细胞色素P450 Panosterol14α-二甲基化酶(P45014DM)抑制剂。 酮康唑或22-羟基胆固醇。 一种或多种促性腺激素和/或一种或多种生长因子优选是EGF和FSH和/或LH的组合。 本发明还涉及如上所述的核成熟抑制物质和一种或多种促性腺激素和/或一种或多种生长因子用于制备卵母细胞体外成熟的细胞培养基的用途 。
    • 90. 发明申请
    • ENUCLEATION OF OOCYTES
    • 植物油的提炼
    • WO1995003398A1
    • 1995-02-02
    • PCT/AU1994000411
    • 1994-07-22
    • MONASH UNIVERSITYTATHAM, Brendan, George
    • MONASH UNIVERSITY
    • C12N05/06
    • A01K67/0275A01K2217/05A61K35/54C12N5/0609C12N2500/32C12N2517/10
    • A process for enucleating oocytes is described. The process includes: providing a source of oocytes; exposing the oocytes to a density gradient to form an oocyte gradient mix; subjecting the oocyte gradient mix to centrifugation to separate an oocyte fraction including enucleated oocytes; and identifying and isolating the enucleated oocytes. Enucleated oocytes produced according to the process have a reduced lipid content compared to enucleated oocytes prepared by conventional methods. They are also capable of electrofusion at amplitudes of 2 kV/cm or less. Enucleated oocytes produced according to the process may be used to prepare nuclear transplantation embryos, which may in turn be used to prepare multiple genetically similar animals.
    • 描述了摘除卵母细胞的过程。 该过程包括:提供卵母细胞源; 将卵母细胞暴露于密度梯度以形成卵母细胞梯度混合物; 对卵母细胞梯度混合物进行离心以分离包括去核卵母细胞的卵母细胞; 并鉴定和分离去核卵母细胞。 与通过常规方法制备的去核卵母细胞相比,根据该方法产生的去核卵母细胞的脂质含量降低。 它们也能够以2kV / cm或更小的振幅进行电熔。 根据该方法产生的去核卵母细胞可用于制备核移植胚,其可以依次用于制备多种遗传相似的动物。